Live from VitaFoods 2013
New science, dosage form drives vitamin K2 interest, NattoPharma CEO says
New research results are driving interest in vitamin K2, according to NattoPharma CEO Hogne Vik. But the company has also developed a new, more potent powder form that is helping to raise the ingredient's profile.
The new results reinforce the ingredient's attractiveness for bone health products. Combined with the new delivery form, the results also open new application doors, such as in sports nutrition.
Vik said these latest developments will help reinvigorate interest in the ingredient, interest which had lagged as a result of some strategic errors on NattoPharma's part concerning the supply of the ingredient. "We were on a good track when you go back to 2010 to sell in the ingredient in the US," Vik said. "Then we made some mistakes. Now we have established a unit in New York and we are very optimistic to move forward with big players in the ingredient market."
